Also known as: VITILIGO

DrugDrug NameDrug Description
DB00337PimecrolimusPimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema).
DB00864TacrolimusTacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. It was discovered in 1984 from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis. Tacrolimus is chemically known as a macrolide. It reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex. This FKBP12-FK506 complex inhibits calcineurin which inhibits T-lymphocyte signal transduction and IL-2 transcription.
DrugDrug NamePhaseStatusCount
DB01281Abatacept1Active Not Recruiting1
DB05676Apremilast2Active Not Recruiting2
DB08877Ruxolitinib2Active Not Recruiting1
DB00654Latanoprost2 / 3Not Yet Recruiting1
DB00864Tacrolimus2 / 3Terminated1
DB00620Triamcinolone2 / 3Recruiting1
DB00316Acetaminophen4Unknown Status1
DB00083Botulinum toxin type A4Completed1
DB01114Chlorphenamine4Unknown Status1
DB00514Dextromethorphan4Unknown Status1
DB00764Mometasone4Unknown Status1
DB00388Phenylephrine4Unknown Status1
DB00337Pimecrolimus4Unknown Status1
DB00864Tacrolimus4Unknown Status2
DB016325-O-phosphono-alpha-D-ribofuranosyl diphosphateNot AvailableNot Yet Recruiting1
DB00588Fluticasone propionateNot AvailableWithdrawn1
DB00864TacrolimusNot AvailableRecruiting1